QuantuMDx appoints Chief Commercial Officer

NEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran has over a decade of experience working within world-leading diagnostic

Share
QuantuMDx SARS-CoV-2 test detects all discovered variants

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new variant

Share
QuantuMDx invests £11 million on scale-up to mass manufacture

NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of its flagship diagnostic device, Q-POC™ and disposable test cassette, to mass

Share
QuantuMDx E-poster presentation: ECCVID 2020

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus. The e-poster focuses on  the independent, multi centre, clinical performance

Share
White paper: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – clinical performance evaluation

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook

Share
QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the

Share
QuantuMDx launches rapid, sensitive SARS-CoV-2 test

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx

Share
QuantuMDx: Leadership changes and business update

QuantuMDx today announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition

Share
QuantuMDx and Ontera collaborate to advance sepsis diagnosis

Improving outcomes for sepsis patients and promoting antibiotic stewardship QuantuMDx and Ontera, have announced a collaboration to create a next-generation solution for blood stream infection and drug resistance detection. The

Share
FIND collaborates with QuantuMDx and SpeeDx

Investigating feasibility of rapid, low-cost STI diagnostics development QuantuMDx and SpeeDx today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and

Share